395 related articles for article (PubMed ID: 30778048)
21. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy.
Zhang X; Qi Z; Yin H; Yang G
Theranostics; 2019; 9(4):1096-1114. PubMed ID: 30867818
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of CD133 Overcomes Cisplatin Resistance Through Inhibiting PI3K/AKT/mTOR Signaling Pathway and Autophagy in CD133-Positive Gastric Cancer Cells.
Lu R; Zhao G; Yang Y; Jiang Z; Cai J; Hu H
Technol Cancer Res Treat; 2019 Jan; 18():1533033819864311. PubMed ID: 31405336
[TBL] [Abstract][Full Text] [Related]
23. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
24. The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF-κB signaling pathway.
He S; Niu G; Shang J; Deng Y; Wan Z; Zhang C; You Z; Shen H
J Exp Clin Cancer Res; 2017 Oct; 36(1):137. PubMed ID: 28978336
[TBL] [Abstract][Full Text] [Related]
25. Endoplasmic reticulum stress promotes autophagy and apoptosis and reverses chemoresistance in human ovarian cancer cells.
Hu JL; Hu XL; Guo AY; Wang CJ; Wen YY; Cang SD
Oncotarget; 2017 Jul; 8(30):49380-49394. PubMed ID: 28537902
[TBL] [Abstract][Full Text] [Related]
26. Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACC.
Kar A; Zhang Y; Yacob BW; Saeed J; Tompkins KD; Bagby SM; Pitts TM; Somerset H; Leong S; Wierman ME; Kiseljak-Vassiliades K
Endocr Relat Cancer; 2019 Oct; 26(10):765-778. PubMed ID: 31325906
[TBL] [Abstract][Full Text] [Related]
27. miR-451a suppresses the proliferation and migration of high-grade serous ovarian cancer by targeting RAB5A through the Ras/Raf/MEK/ERK pathway.
Liu S; Wang K; Zhao Z; Pang Y; Liu F; Wang P; Wang Z; Yang X
J Gene Med; 2024 Jan; 26(1):e3649. PubMed ID: 38282155
[TBL] [Abstract][Full Text] [Related]
28. Hyper-phosphorylation of Sequestosome-1 Distinguishes Resistance to Cisplatin in Patient Derived High Grade Serous Ovarian Cancer Cells.
Nguyen EV; Huhtinen K; Goo YA; Kaipio K; Andersson N; Rantanen V; Hynninen J; Lahesmaa R; Carpen O; Goodlett DR
Mol Cell Proteomics; 2017 Jul; 16(7):1377-1392. PubMed ID: 28455291
[TBL] [Abstract][Full Text] [Related]
29. TIPE2 suppressed cisplatin resistance by inducing autophagy via mTOR signalling pathway.
Guo H; Ren H; Li J; Hao M; Hao J; Ren H; Guo L; Liu R
Exp Mol Pathol; 2020 Apr; 113():104367. PubMed ID: 31917287
[TBL] [Abstract][Full Text] [Related]
30. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
31. Induction of autophagy counteracts the anticancer effect of cisplatin in human esophageal cancer cells with acquired drug resistance.
Yu L; Gu C; Zhong D; Shi L; Kong Y; Zhou Z; Liu S
Cancer Lett; 2014 Dec; 355(1):34-45. PubMed ID: 25236911
[TBL] [Abstract][Full Text] [Related]
32. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G
Cell Signal; 2020 Apr; 68():109539. PubMed ID: 31935430
[TBL] [Abstract][Full Text] [Related]
33. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
34. miR-130a upregulates mTOR pathway by targeting TSC1 and is transactivated by NF-κB in high-grade serous ovarian carcinoma.
Wang Y; Zhang X; Tang W; Lin Z; Xu L; Dong R; Li Y; Li J; Zhang Z; Li X; Zhao L; Wei JJ; Shao C; Kong B; Liu Z
Cell Death Differ; 2017 Dec; 24(12):2089-2100. PubMed ID: 28800130
[TBL] [Abstract][Full Text] [Related]
35. [Effect and mechanism of endoplasmic reticulum stress on cisplatin resistance in ovarian carcinoma].
Tian J; Hu X; Qu Q
Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):324-8. PubMed ID: 25030585
[TBL] [Abstract][Full Text] [Related]
36. TGF β1 promotes the polarization of M2-type macrophages and activates PI3K/mTOR signaling pathway by inhibiting ISG20 to sensitize ovarian cancer to cisplatin.
Wu J; Jiang L; Wang S; Peng L; Zhang R; Liu Z
Int Immunopharmacol; 2024 Jun; 134():112235. PubMed ID: 38761779
[TBL] [Abstract][Full Text] [Related]
37. The role of mTOR during cisplatin treatment in an in vitro and ex vivo model of cervical cancer.
Leisching GR; Loos B; Botha MH; Engelbrecht AM
Toxicology; 2015 Sep; 335():72-8. PubMed ID: 26201060
[TBL] [Abstract][Full Text] [Related]
38. FAM83D inhibits autophagy and promotes proliferation and invasion of ovarian cancer cells via PI3K/AKT/mTOR pathway.
Zhu H; Diao S; Lim V; Hu L; Hu J
Acta Biochim Biophys Sin (Shanghai); 2019 May; 51(5):509-516. PubMed ID: 30939187
[TBL] [Abstract][Full Text] [Related]
39. PBK drives PARP inhibitor resistance through the TRIM37/NFκB axis in ovarian cancer.
Ma H; Qi G; Han F; Peng J; Yuan C; Kong B
Exp Mol Med; 2022 Jul; 54(7):999-1010. PubMed ID: 35859118
[TBL] [Abstract][Full Text] [Related]
40. Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer.
Andorfer P; Heuwieser A; Heinzel A; Lukas A; Mayer B; Perco P
BMC Syst Biol; 2016 Apr; 10():33. PubMed ID: 27090655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]